Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Current Deferred Revenue data on file, last reported at $402000.0 in Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $402000.0, down 94.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $402000.0 (down 94.53% YoY), and the FY2025 annual result was $402000.0, down 94.23% from the prior year.
• Current Deferred Revenue eased to $402000.0 in Q4 2025 per TLX's latest filing, from $7.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.4 million in Q4 2024 and troughed at $402000.0 in Q4 2025.
• A 3-year average of $5.0 million and a median of $7.2 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue gained 2.77% in 2024, then plunged 94.53% in 2025.
• A 3-year view of Current Deferred Revenue shows it stood at $7.2 million in 2023, then advanced by 2.77% to $7.4 million in 2024, then sank by 94.53% to $402000.0 in 2025.
• Business Quant data shows TLX's Current Deferred Revenue at $402000.0 in Q4 2025, $7.4 million in Q4 2024, and $7.2 million in Q4 2023.